The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples
Blood Advances, 2019•Elsevier
Methods Clinical data and PB mononuclear cell samples were provided by the Blood and
Marrow Clinical Trials Network (BMT CTN). BMT CTN‐0201 was a phase 3 randomized
multicenter trial (2004-2009, 551 patients) comparing unrelated donor BM vs PB HCTs, with
2‐year survival as the primary end point. 14 The trial demonstrated similar rates of acute
graft-versus-host disease (aGVHD) but higher rates of chronic GVHD among PB graft
recipients. An analysis of infections 15 showed the BM group with a higher 2-year …
Marrow Clinical Trials Network (BMT CTN). BMT CTN‐0201 was a phase 3 randomized
multicenter trial (2004-2009, 551 patients) comparing unrelated donor BM vs PB HCTs, with
2‐year survival as the primary end point. 14 The trial demonstrated similar rates of acute
graft-versus-host disease (aGVHD) but higher rates of chronic GVHD among PB graft
recipients. An analysis of infections 15 showed the BM group with a higher 2-year …
Methods
Clinical data and PB mononuclear cell samples were provided by the Blood and Marrow Clinical Trials Network (BMT CTN). BMT CTN‐0201 was a phase 3 randomized multicenter trial (2004-2009, 551 patients) comparing unrelated donor BM vs PB HCTs, with 2‐year survival as the primary end point. 14 The trial demonstrated similar rates of acute graft-versus-host disease (aGVHD) but higher rates of chronic GVHD among PB graft recipients. An analysis of infections 15 showed the BM group with a higher 2-year cumulative incidence of all infections and bacterial infections but similar 2-year cumulative incidence of CMV and fungal infections.
Elsevier
